神经营养性角膜病变综述
神经营养性角膜病变(NK)指伴角膜感觉减退或消失的角膜上皮病变,可导致上皮缺损,伴或不伴角膜基质溃疡(溶解)。感觉神经兼具伤害感受与营养功能,两者可独立或同时受累。轻、中、重度NK表现不同,中重度可严重影响视力与生活质量。现有润滑、抗炎、抗生素、抗蛋白酶等治疗仅提供非特异性、可能暂时的缓解,接触镜、泪点栓、肉毒毒素眼睑闭合及睑缘缝合、结膜瓣、羊膜等成功率较高但常遮挡视线,角膜手术失败风险高。生物制剂如模拟硫酸肝素的生物聚合物、辅酶Q10、抑制连接蛋白43表达的反义寡核苷酸均展现前景,重组神经生长因子(cenegermin)已获批用于人体,靶向神经病理,有望针对潜在缺陷成为NK的特异性治疗。
要点
- NK由角膜感觉减退或消失伴上皮病变所致,可进展为基质溶解与穿孔。
- 中重度NK可严重影响视力与生活质量。
- cenegermin已获批用于人体,靶向神经病理,有望成为NK特异性治疗。
核心结论
- 重组神经生长因子(cenegermin)已获批用于人体,靶向神经病理,有潜力针对潜在缺陷并成为NK的特异性治疗。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 感觉神经的伤害感受与营养功能可独立或同时受累,营养功能丧失致上皮破损、基质暴露而易被酶降解。
- 神经病理可从神经磨损到异常再生,症状从感觉缺失到感觉过敏/痛觉异常。
- 多种全身与眼部疾病、手术及含防腐剂药物可导致NK。
- NK可分为轻度(上皮与泪膜改变)、中度(上皮缺损不愈合)、重度(基质溶解与穿孔)。
- 中重度NK可严重影响视力并对生活质量造成不良影响。
关键数值与推荐
- 原文未报告具体数值或推荐条款。
临床怎么用
- 润滑剂(从人工泪液到血清/血浆滴眼液)、抗炎药、抗生素与抗蛋白酶均提供非特异性缓解,可能为暂时性。
- 接触镜、泪点栓、肉毒毒素眼睑闭合及睑缘缝合、结膜瓣、羊膜等成功率较高,但常以遮挡视线为代价。
- 在眼表干燥且感觉减退时行角膜手术失败风险高。
- 模拟硫酸肝素的生物聚合物、辅酶Q10及抑制连接蛋白43表达的反义寡核苷酸均展现前景。
- 重组神经生长因子(cenegermin)已获批用于人体,靶向神经病理,有望成为NK特异性治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neurotrophic Keratopathy (NK) refers to a condition where corneal epitheliopathy leading to frank epithelial defect with or without stromal ulceration (melting) is associated with reduced or absent corneal sensations. Sensory nerves serve nociceptor and trophic functions, which can be affected independently or simultaneously. Loss of trophic function and consequent epithelial breakdown exposes the stroma making it susceptible to enzymatic degradation. Nerve pathology can range from attrition to aberrant re-generation with corresponding symptoms from anaesthesia to hyperaesthesia/allodynia. Many systemic and ocular conditions, including surgery and preserved medications can lead to NK. NK can be mild (epithelium and tear film changes), moderate (non-healing epithelial defect) or severe (stromal melting and perforation). Moderate and severe NK can profoundly affect vision and adversely impact on the quality of life. Medical management with lubricating agents from artificial tears to serum/plasma drops, anti-inflammatory agents, antibiotics and anti-proteases all provide non-specific relief, which may be temporary. Contact lenses, punctal plugs, lid closure with botulinum toxin and surgical interventions like tarsorrhaphy, conjunctival flaps and amniotic membrane provide greater success but often at the cost of obscuring sight. Corneal surgery in a dry ocular surface with reduced sensation is at high risk of failure. The recent advent of biologicals such as biopolymers mimicking heparan sulfate; coenzyme Q10 and antisense oligonucleotide that suppress connexin 43 expression, all offer promise. Recombinant nerve growth factor (cenegermin), recently approved for human use targets the nerve pathology and has the potential of addressing the underlying deficit and becoming a specific therapy for NK.
引用
- Dua HS, Said DG, Messmer EM, et al. Neurotrophic keratopathy. Prog Retin Eye Res. 2018. PMID: 29698813. doi:10.1016/j.preteyeres.2018.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。